A Randomized, Single Center, Open-label, Phase I Study to Evaluate the Effect of Food and Fasting on the Pharmacokinetics of ASC41 Tablets in Healthy Volunteers
Latest Information Update: 05 Feb 2021
At a glance
- Drugs ASC 41 (Primary)
- Indications Hyperlipidaemia; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Obesity
- Focus Pharmacokinetics
- Sponsors Gannex Pharma
- 03 Feb 2021 Status changed from recruiting to completed.
- 05 Jan 2021 New trial record